Age-related Macular Degeneration (AMD) - Pipeline Insight, 2026

DelveInsight's, "Age-related Macular Degeneration (AMD) - Pipeline Insight, 2026" report provides comprehensive insights about 90+ companies and 100+ pipeline drugs in Age-related Macular Degeneration (AMD) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered:

• Global coverage

Age-related Macular Degeneration (AMD): Understanding

Age-related Macular Degeneration (AMD): Overview

Age-related macular degeneration (AMD) is a progressive disease affecting the macula and is a major cause of central vision impairment among older adults. The condition primarily involves the outer retina, particularly the photoreceptors and retinal pigment epithelium (RPE), with the early accumulation of drusen reflecting impaired clearance of cellular debris. With disease progression, RPE dysfunction, chronic inflammation, and compromised choroidal circulation contribute to photoreceptor damage and declining vision. AMD generally progresses from early to advanced stages and occurs as either dry AMD, which can progress to geographic atrophy, or wet/neovascular AMD, which is characterized by abnormal blood-vessel formation. Patients commonly develop blurred or distorted central vision and scotomas, while peripheral vision is generally maintained; visual deterioration may be more rapid in wet AMD because of retinal fluid leakage or hemorrhage.

AMD pathophysiology is multifactorial and involves progressive damage to the outer retina resulting from cumulative stress on the RPE, alterations in Bruch's membrane, and increasing drusen deposition. Age-associated RPE dysfunction impairs retinal homeostasis and waste removal, while oxidative stress and persistent inflammatory activation further damage retinal cells. Disruption of the RPE-Bruch's membrane-choroid interface compromises the delivery of oxygen and nutrients to photoreceptors, accelerating retinal degeneration. In advanced dry AMD, this process can lead to extensive RPE and photoreceptor loss, resulting in geographic atrophy. In wet AMD, increased vascular endothelial growth factor (VEGF) signaling promotes the development of abnormal and fragile blood vessels that can leak fluid or blood and eventually cause retinal fibrosis and scarring.

Diagnosis of AMD involves clinical examination combined with retinal imaging and functional assessment. Evaluation generally begins with a detailed medical and ocular history and a dilated fundus examination to identify characteristic findings such as drusen, pigmentary abnormalities, geographic atrophy, or evidence of neovascularization. Visual acuity testing and tools such as the Amsler grid can help detect changes in central vision, including distortion and scotomas. Optical coherence tomography (OCT) is particularly important for evaluating retinal structure and identifying intraretinal or subretinal fluid associated with neovascular AMD. Fundus photography and, when required, additional imaging techniques can further characterize retinal abnormalities and help differentiate between dry and wet disease.

Treatment of AMD is determined by the disease subtype and stage. Wet AMD is primarily treated with intravitreal anti-VEGF therapies, including agents such as aflibercept, which inhibit pathological angiogenesis and reduce retinal fluid leakage, with treatment intervals adjusted according to disease activity. For dry AMD, management traditionally includes regular monitoring, modification of risk factors such as smoking, and nutritional supplementation with the AREDS2 formulation for appropriate patients. The therapeutic landscape for geographic atrophy has recently expanded with the introduction of complement pathway inhibitors, which can slow the progression of atrophic lesions in selected patients. Meanwhile, multiple investigational approaches targeting complement activation, inflammation, oxidative stress, neuroprotection, and other disease mechanisms remain under clinical development.

"Age-related Macular Degeneration (AMD)- Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Age-related Macular Degeneration (AMD) pipeline landscape is provided which includes the disease overview and Age-related Macular Degeneration (AMD) treatment guidelines. The assessment part of the report embraces, in depth Age-related Macular Degeneration (AMD) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Age-related Macular Degeneration (AMD) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights:

• The companies and academics are working to assess challenges and seek opportunities that could influence Age-related Macular Degeneration (AMD) R&D. The therapies under development are focused on novel approaches to treat/improve Age-related Macular Degeneration (AMD).

Age-related Macular Degeneration (AMD) Emerging Drugs Chapters

This segment of the Age-related Macular Degeneration (AMD) report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Age-related Macular Degeneration (AMD) Emerging Drugs

Elamipretide: Mighty Therapeutics

Elamipretide is an investigational mitochondria-targeted peptide being developed by Mighty Therapeutics for dry age-related macular degeneration (AMD), including geographic atrophy. The therapy targets mitochondrial dysfunction by interacting with cardiolipin in the inner mitochondrial membrane, with the aim of improving mitochondrial function and protecting retinal cells and photoreceptors from degeneration. Elamipretide is currently being evaluated in the Phase III ReNEW study as a once-daily 40-mg subcutaneous treatment for dry AMD, with the trial evaluating photoreceptor loss, safety and pharmacokinetics.

4D-150: 4D Molecular Therapeutics

4D-150 is an investigational AAV-based intravitreal gene therapy developed by 4D Molecular Therapeutics for neovascular (wet) age-related macular degeneration (AMD). It uses the company's proprietary R100 vector to deliver two therapeutic transgenes designed to provide sustained expression within retinal cells and suppress four VEGF-family members. The therapy is designed as a single, low-dose intravitreal injection with the potential to provide durable anti-angiogenic activity and reduce dependence on repeated anti-VEGF injections. 4D-150 is currently being evaluated in Phase III 4FRONT-1 and 4FRONT-2 trials for wet AMD, following clinical development in the Phase I/II PRISM study.

MK-8748: Merck

MK-8748 is Merck's investigational bispecific antibody being developed for neovascular (wet) age-related macular degeneration (AMD). It is designed to activate Tie2 while simultaneously inhibiting VEGF, aiming to improve retinal and choroidal vascular stability and reduce pathological macular fluid leakage. The program was acquired through Merck's acquisition of EyeBio and is being evaluated in Phase II/III clinical development. MK-8748 is currently being investigated in the TORRONTES and MALBEC studies for neovascular AMD.

SAR402663: Sanofi

SAR402663 is Sanofi's investigational AAV-based gene therapy being developed for neovascular (wet) age-related macular degeneration (AMD). It delivers genetic material encoding soluble FLT01, designed to inhibit VEGF, thereby suppressing abnormal blood-vessel growth and reducing vascular leakage in the retina. The therapy is intended as a one-time intravitreal treatment, potentially reducing the treatment burden associated with repeated anti-VEGF injections. SAR402663 is currently being evaluated in the Phase II stage for the treatment of neovascular (wet) age-related macular degeneration (AMD).

Xelafaslatide: ONL Therapeutics

ONL-1204 (xelafaslatide) is an investigational, first-in-class small-peptide inhibitor of the Fas receptor being developed by ONL Therapeutics for geographic atrophy (GA) associated with dry AMD. It is designed to inhibit Fas-mediated apoptosis and inflammatory signaling, thereby protecting retinal cells, including photoreceptors and RPE cells, from degeneration. Following encouraging Phase Ib findings showing that ONL-1204 was generally well tolerated with signals of reduced GA lesion growth, it is being evaluated in the Phase II clinical trial.

HG202: HuidaGene Therapeutics

HG202 is an investigational CRISPR/Cas13 RNA-editing gene therapy developed by HuidaGene Therapeutics for neovascular (wet) age-related macular degeneration (nAMD). It uses a single AAV vector to deliver a high-fidelity Cas13 system designed to partially knock down VEGFA mRNA, thereby reducing VEGF-driven abnormal blood-vessel growth and leakage. HG202 is intended as a one-time treatment, with the potential to provide sustained VEGF suppression and reduce the need for repeated anti-VEGF injections. It is being evaluated in the Phase I BRIGHT study to assess safety, tolerability, visual outcomes, and the need for supplemental anti-VEGF treatment in patients with nAMD.

Age-related Macular Degeneration (AMD): Therapeutic Assessment

This segment of the report provides insights about the different Age-related Macular Degeneration (AMD) drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Age-related Macular Degeneration (AMD)
• There are approx. 90+ key companies which are developing the therapies for Age-related Macular Degeneration (AMD). The companies which have their Age-related Macular Degeneration (AMD) drug candidates in the most advanced stage, i.e. Phase III include, Mighty Therapeutics.
• Phases

DelveInsight's report covers around 100+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Age-related Macular Degeneration (AMD) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical
• Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Age-related Macular Degeneration (AMD): Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Age-related Macular Degeneration (AMD) therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Age-related Macular Degeneration (AMD) drugs.

Age-related Macular Degeneration (AMD) Report Insights

• Age-related Macular Degeneration (AMD) Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Age-related Macular Degeneration (AMD) Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions:

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Age-related Macular Degeneration (AMD) drugs?
• How many Age-related Macular Degeneration (AMD) drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Age-related Macular Degeneration (AMD)?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Age-related Macular Degeneration (AMD) therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Age-related Macular Degeneration (AMD) and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Mighty Therapeutics
• Sanofi
• Merck
• HuidaGene Therapeutics
• ONL Therapeutics
• 4D Molecular Therapeutics
• Evergreen Therapeutics
• Caregen Co. Ltd.
• SCAI Therapeutics
• Frontera Therapeutics
• Chengdu Origen Biotechnology Co., Ltd.
• BenoBio
• Skyline Therapeutics
• Perceive Biotherapeutics
• Sinocelltech Ltd.
• Character Biosciences
• Amarna Therapeutics
• Avirmax Biopharma
• Galimedix Therapeutics
• Rallybio
• Ikarovec
• 4P Pharma
• Surrozen
• Beacon Therapeutics
• Ray Therapeutics

Key Products

• Elamipretide
• SAR402663
• MK-8748
• HG202
• Xelafaslatide
• 4D-150
• EG-301
• CG-P5
• SCAI 010
• FT-003
• KH658
• BBC1501
• SKG0106
• VOY-101
• SCT520FF
• CTX203
• AMA004
• ABI-201
• GAL-101
• RLYB114
• IKAR-002
• 4P020
• SZN-8141
• BTX-001
• RTX-021